This review looks at how doctors can better understand different types of data when treating patients with resectable non-small cell lung cancer. Specifically, it looks at how tissue samples, blood tests, and imaging results can sometimes give different signals after a patient receives neoadevuant chemoimmunotherapy.
Researchers found that while clearing certain markers in the blood is a sign of a molecular response, it does not prove that all cancer cells have been removed from the tissue. Additionally, some imaging results might show abnormalities even after a tumor has shrunk. This can happen because the body is undergoing inflammatory or reparative changes in the area.
Because these different tests can sometimes provide conflicting information, it is important for medical teams to look at all data together. This review provides a framework for doctors to better interpret these mixed signals. This helps them make more informed decisions about the next steps in a patient's care.